Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
ARN-509 Chemical Structure
|Product name: ARN-509|
|Cat. No.: HY-16060|
ARN-509 is a selective and competitive androgen receptor inhibitor with IC50 of 16 nM, useful for prostate cancer treatment.
IC50 value: 16 nM
Target: androgen receptor
ARN-509 is an androgen receptor antagonist with potential antineoplastic activity. ARN-509 binds to AR in target tissues thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes. This ultimately inhibits the expression of genes that regulate prostate cancer cell proliferation and may lead to an inhibition of cell growth in AR-expressing tumor cells.
|M.Wt||477.43||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
DMSO 15 mg/mL Ethanol 5 mg/mL
|1 mg||5 mg||10 mg|
|1 mM||2.0945 mL||10.4727 mL||20.9455 mL|
|5 mM||0.4189 mL||2.0945 mL||4.1891 mL|
|10 mM||0.2095 mL||1.0473 mL||2.0945 mL|
|Product Name||Sponsor Only||Condition||Start Date||End Date||Phase||Last Change Date|
|ARN-509||Aragon Pharmaceuticals Inc||Hormone refractory prostate cancer||31-JUL-10||30-JUN-13||Phase 2||17-SEP-13|
|Aragon Pharmaceuticals Inc||31-MAR-13||30-JUN-13||Phase 1||17-SEP-13|
|Aragon Pharmaceuticals Inc||Hormone refractory prostate cancer||31-OCT-13||31-DEC-16||Phase 3||05-NOV-13|
|Aragon Pharmaceuticals Inc; Johnson & Johnson||Hormone refractory prostate cancer||28-FEB-13||01-FEB-14||Phase 1||07-OCT-13|
|Aragon Pharmaceuticals Inc||Hormone dependent prostate cancer||28-FEB-13||28-FEB-18||Phase 2||18-OCT-13|
. Schweizer MT, Antonarakis ES. Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol. 2012 Aug;4(4):167-78.
Andarine (S-4) is an investigational selective androgen receptor modulator (SARM) and an active partial agonist.
ASC-J9(GO-Y025; Dimethylcurcumin), is antitumor agent; ASC-J9 suppresses castration-resistant prostate cancer growth via degradation of full-length and splice variant androgen receptors.
AZD3514 is a potent and oral androgen receptor downregulator with Ki of 2.2 (mu)M and has ability of reducing AR protein expression.
Bicalutamide(Casodex) is an oral non-steroidal anti-androgen for prostate cancer; binds to the androgen receptor.
BMS-564929 is a novel, highly potent, orally active, nonsteroidal tissue selective androgen receptor (AR) modulator (Ki= 2.11 nM).
Cortexolone 17 alpha-propionate(CB-03-01) is a new topical and peripherally selective androgen antagonist.
Cyproterone acetate is an androgen receptor (AR) antagonist with IC50 of 7.1 nM, as well as a weak progesterone receptor agonist with weak pro-gestational and glucocorticoid activity.
Danazol is a derivative of the synthetic steroid ethisterone, that suppresses the production of gonadotrophins, and has some weak androgenic effects.
Epiandrosterone is a steroid hormone with weak androgenic activity. Epiandrosterone is naturally produced by the enzyme 5(alpha)-reductase from the adrenal hormone DHEA.
Flutamide is an antiandrogen drug, with its active metablolite binding at androgen receptor with Ki values of 55 nM, and primarily used to treat prostate cancer.